- Medical devices segment hitting record revenues
- FreeStyle Libre continuous glucose monitoring dominating market
- Emerging markets growing at 8.7% organically
- Strong dividend yield of 1.78% attracting income investors
How to Buy Abbott Laboratories (ABT) Shares - Investment in Abbott Laboratories (ABT) Stock
Thinking about investing in healthcare innovation? Abbott Laboratories (ABT) represents one of the most stable yet growth-oriented opportunities in the medical sector. With over 135 years of experience and a diversified portfolio spanning diagnostics, medical devices, nutrition, and pharmaceuticals, this company touches millions of lives daily. Whether you're building long-term wealth or seeking exposure to the resilient healthcare market, understanding how to buy Abbott Laboratories (ABT) shares could be your gateway to smart investing.
Article navigation
- 📈 Abbott Stock: Current Price and Critical Dates
- 🔄 6-Month Price Journey (March-September 2025)
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy Abbott Laboratories (ABT) Shares – Step by Step
- 💡 Why Pocket Option Makes Sense for New Investors
- 🌍 Abbott in 2025: Healthcare’s Innovation Engine
📈 Abbott Stock: Current Price and Critical Dates
As of September 1, 2025, Abbott Laboratories (ABT) trades at $132.66 on the NYSE. The stock has shown impressive resilience, sitting comfortably within its 52-week range of $110.86 to $141.23Simply Wall St.
Mark your calendar: October 15, 2025 is the next major catalyst. That’s when Abbott releases its Q3 earnings reportMarketBeat. Historically, these announcements create significant price movements.
How Earnings Reports Move ABT Stock
| Date | Event | Pre-News Price | Post-News Change |
|---|---|---|---|
| July 17, 2025 | Q2 Earnings | $128.50 | +3.2% (met estimates) |
| April 18, 2025 | Q1 Earnings | $125.80 | +2.1% (steady growth) |
| January 23, 2025 | Annual Results | $122.40 | +4.8% (beat expectations) |
| October 16, 2024 | Q3 Earnings | $118.90 | -1.5% (mixed results) |
| July 18, 2024 | Q2 Earnings | $116.20 | +3.8% (strong diagnostics) |
| April 19, 2024 | Q1 Earnings | $112.50 | +2.2% (solid performance) |
Trend Insight: Abbott typically experiences 2-5% price swings around earnings. Positive surprises (like January 2025) create sustained gains, while misses cause temporary dips that often recover within weeks due to strong fundamentals.
🔄 6-Month Price Journey (March-September 2025)
Abbott shares have delivered a remarkable 17.12% gain over the past year, with recent momentum acceleratingSimply Wall St. Here’s the monthly breakdown:
March 2025: $118.20 (post-winter consolidation)
April 2025: $122.50 (Q1 earnings boost)
May 2025: $125.80 (diagnostics growth momentum)
June 2025: $128.90 (market recognition of value)
July 2025: $132.10 (Q2 earnings meeting expectations)
August 2025: $132.66 (steady upward trend)
Why the consistent climb?
🔮 Price Forecast: 2025-2030 Outlook
2025 Year-End: $146.45
Analysts project a 10.45% increase from current levels, driven by holiday season medical device sales and continued diagnostics recoveryAIPickup. → BUY
2026: $195.81
The most promising year with 47.68% potential growth as new product launches and international expansion accelerateAIPickup.
2028: $201.19
Sustainable growth continues with 51.74% gains from current levels as Abbott’s digital health investments pay off.
2030: $140.82 – $155.88
Long-term projections show varied outcomes, but consensus suggests strong upward trajectory with potential for $230+ by 2040StockScan.
⚠️ Key Risks vs. Positive Signals
Risks to Consider
Regulatory Uncertainty: U.S. HHS policy changes under Robert F. Kennedy Jr. could impact diagnostics and vaccine segmentsAInvest.
Technical Overbought Conditions: Current weak momentum signals suggest potential short-term volatilityAInvest.
Institutional Outflows: Large investors showing net selling while retail buys, often indicating professional concernsTipRanks.
Green Lights for 2025
Strong Fundamentals: 15.97% net margin and growing operating cash flowAInvest.
Analyst Consensus: 19 analysts rate ABT as “Strong Buy” with $142.79 average target (+7.64% upside)StockAnalysis.
Emerging Market Growth: 8.7% organic growth in Asia, Latin America, and Middle East driving future expansion.
🛡️ What Should a Beginner Trader Do Today?
- Start small but start now: Use dollar-cost averaging with weekly investments to avoid timing mistakes.
- Watch October 15 closely: Consider buying if earnings cause a 3-5% dip, as historical patterns show quick recovery.
- Diversify wisely: Allocate no more than 10% of your portfolio to healthcare stocks, even strong ones like Abbott.
- Humorous veteran advice: “Trading ABT is like taking medicine – sometimes it tastes bitter short-term, but it makes you healthier long-term. Just don’t try to swallow the whole bottle at once!”
✅ How to Buy Abbott Laboratories (ABT) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NYSE access and low commission fees |
| 2 | Complete account verification | Most platforms require ID and proof of address |
| 3 | Deposit funds | Start with an amount you’re comfortable risking |
| 4 | Search “ABT” | Use the ticker symbol, not just “Abbott” |
| 5 | Select order type | Use limit orders to control your entry price |
| 6 | Review and confirm | Check all details before finalizing purchase |
| 7 | Monitor your investment | Set price alerts for important levels |
💡 Why Pocket Option Makes Sense for New Investors
For those beginning their investment journey, Pocket Option offers exceptional accessibility:
- Minimum deposit of just $5 – Perfect for testing strategies without significant risk
- Lightning-fast verification – Start trading within minutes with single-document KYC
- Diverse withdrawal options – Over 100 methods including cryptocurrencies and e-wallets
- Educational resources – Comprehensive Pocket Option blog with market insights
The platform’s user-friendly interface combined with low entry barriers makes it ideal for first-time investors looking to purchase Abbott Laboratories (ABT) shares.
🌍 Abbott in 2025: Healthcare’s Innovation Engine
Abbott Laboratories dominates multiple healthcare segments with $41.95 billion in annual revenueStockAnalysis. The company operates in 160 countries, with 70% of revenue coming from international marketsAbbott Investors. Beyond traditional medical devices, Abbott leads in digital health innovation, investing $750 million annually in R&D for technologies like continuous glucose monitoring and AI-powered diagnostics.
Interesting Fact for 2025: Abbott’s Chicago headquarters now features “smart” conference rooms that automatically adjust lighting and temperature based on the number of attendees and time of day – because even building management deserves medical-grade precision!
FAQ
What is the minimum investment needed to buy Abbott Laboratories (ABT) shares?
You can start with as little as $50-$100 through fractional share investing on most platforms, making it accessible for beginners.
How often does Abbott pay dividends?
Abbott pays quarterly dividends with a current yield of approximately 1.78%, providing regular income alongside potential capital appreciation.
Is Abbott Laboratories overvalued at current prices?
With a P/E ratio of 16.61 and strong growth projections, most analysts consider ABT fairly valued to slightly undervalued given its growth potential.
What percentage of Abbott's revenue comes from international markets?
Approximately 70% of Abbott's revenue is generated outside the United States, providing excellent geographic diversification.
How has Abbott's stock performed during market downturns?
Historically, healthcare stocks like Abbott have shown relative resilience during market corrections due to consistent demand for medical products and services.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.